Home / Healthcare/ Johnson & Johnson says to work on India compensation for recalled hip implants

Johnson & Johnson says to work on India compensation for recalled hip implants


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 12 September 2018 00:00


Mumbai (Reuters): Johnson & Johnson (J&J) said on Friday it would work with the Indian government to compensate patients who suffered from artificial hip implants the US healthcare company recalled eight years ago.

Last month, a government panel recommended that J&J pay compensation of at least INR 2 million ($27,812) to each patient who received an ASR hip implant in India, an estimated 4,700 people. The federal government has asked states to help the patients get relief soon.

“We have always been and continue to be fully committed to supporting all ASR patients in India, and the rest of the world,” a J&J spokeswoman said in a statement emailed to Reuters.

“In light of the recent committee report, we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need,” she added.

The ASR hip implants were recalled in 2010 after data suggested they failed at a higher-than-expected rate.

In 2013, the firm agreed to pay nearly $2.5 billion to settle thousands of lawsuits from patients in the United States who said they were injured by the implants.

In India, the company paid $2 million to patients for repeat surgeries and about $250,000 in related diagnostic costs under its ASR reimbursement program, but the government panel criticised J&J for offering no compensation.

About 93,000 people worldwide received ASR implants, the panel said in its report to the government, about 4,700 of them in India.

Metal hip implant systems such as ASR were designed to be more durable than a traditional metal-on-plastic, ball-and-socket design. But many Indian patients suffered adverse reactions to the implant, the panel said.

J&J entered the Indian market in 1947 when it started selling its now-ubiquitous baby powder. The company has in recent years faced issues such as price caps on medical devices.

 


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Untruth is the crisis

Tuesday, 13 November 2018

Political language, said George Orwell, is designed to make lies sound truthful, murder respectable, and to give an appearance of solidity to pure wind. Dr. Sarath Amunugama is the subject of this essay. In addition to his current incarnation of a p


Rise, Sri Lankans – our country needs you now!

Tuesday, 13 November 2018

I am sick, tired and bloody fed up of reading and listening to pessimistic tales of woe on the unprecedented crisis we and our country are facing at this dark moment in time. I am also fed up to the back teeth with reading and listening to lamentatio


Ranil abused and subverted parliamentary democracy

Tuesday, 13 November 2018

TIME: What was the immediate reason for calling an election? President Kumaratunga: I was forced into it by a total breakdown of cohabitation in Government. The Prime Minister (Ranil Wickremesinghe) was determined to harass me and chase me out. He ha


The Bench must ensure that the judges will continue to be trusted

Monday, 12 November 2018

In the backdrop of the recent developments and the strong arguments that have been presented against the dissolution of Parliament saying the President has no constitutional power to do so, before four and a half years into a Parliamentary term, as s


Columnists More